Previous individual trials, due to their limitations and small sample sizes, had not been successful in indicating a significant benefit in the implementation of guided selection of antiplatelet therapy; a large, randomized trial examining a genotype-guided selection of antiplatelet therapy, the TAILOR-PCI (Tailored Antiplatelet Therapy Following PCI) trial, did observe a 34% relative reduction in ischemic events when carriers of CYP2C19 loss-of-function alleles were treated with ticagrelor relative to clopidogrel, but it failed to reach statistical significance [ 21 ].
← all excerpts
Does individualized guided selection of antiplatelet therapy improve outcomes after percutaneous coronary intervention? A systematic review and meta-analysis.
1
—
—